NCT05640830View on ClinicalTrials.gov

Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
HER2-positive Advanced Gastric Cancer
Interventions
DRUG

trastuzumab, bevacizumab with paclitaxel (triple combination)

Trastuzumab 4 mg/kg Day 1, 15 Bevacizumab 5 mg/kg Day 1, 15 Paclitaxel 80 mg/m2 Day 1, 8, 15 every 4 weeks

Trial Locations (1)

110-746

RECRUITING

Kangbuk Samsung Hospital, Seoul

All Listed Sponsors
lead

Kangbuk Samsung Hospital

OTHER